Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women

Kars, Marleen; Pijl, Hanno; Cohen, Adam F.; Frölich, Marijke; Schoemaker, Rik C.; Brandenburg, Helen; Meinders, A. E.

doi:10.1046/j.1365-2265.1996.727548.x

Cited by 7 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the GH response to GHRH is increased in the presence of dexfenfluramine in patients with android obesity and in those with a reduction of insulin levels (although this latter response may have been influenced by dietary habits) (64). Other authors have not observed any increrase in the GH response to GHRH in obese women under treatment with dexfenfluramine (63).…”

Section: Pharmacological Agents Modulating Energetic Homeostasismentioning

confidence: 92%

“…In addition, the increase of adrenocorticotrophin (ACTH) and cortisol after naloxone administration (in both obese and non‐obese women) was attenuated through a 7‐d treatment with dexfenfluramine (61). ACTH and cortisol response to adrenocorticotrophin releasing hormone (CRH) were not affected by treatment with dexfenfluramine (63). However, the GH response to GHRH is increased in the presence of dexfenfluramine in patients with android obesity and in those with a reduction of insulin levels (although this latter response may have been influenced by dietary habits) (64).…”

Section: Pharmacological Agents Modulating Energetic Homeostasismentioning

confidence: 99%

See 1 more Smart Citation

Treatment of obesity: an update on anti‐obesity medications

2003

View full text Add to dashboard Cite

The information presented in this article provides an overview of physiological agents, therapeutics in current use, and medications that have been extensively used in the past but are no longer available, or are not classically considered as anti-obesity drugs. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral action energetic homeostasis (nutrients, monoamines and peptides), and on beta-phenethylamine pharmacological-derivative agents (fenfluramine, dexfenfluramine, phentermine, diethylpropion, fenproporex and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrine, phenylpropanolamine), a phenylpropanolamine oxy-tri-fluor-phenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials longer than 10 weeks in duration is also presented for medications used in the management of obesity.

show abstract

Section: Pharmacological Agents Modulating Energetic Homeostasismentioning

confidence: 92%

Section: Pharmacological Agents Modulating Energetic Homeostasismentioning

confidence: 99%

Treatment of obesity: an update on anti‐obesity medications

2003

View full text Add to dashboard Cite

show abstract

“…The same agent did not affect ACTH and cortisol responses to CRH (58); however, GH response to GHRH was shown to be increased in patients with android obesity, concomitantly with reduction in insulin levels (although the latter may be influenced by dietary habits) (46). Other authors have not detected increase in GH response to GHRH in obese women treated with dexfenfluramine (47).…”

Section: Endocrine and Metabolic Effectsmentioning

confidence: 98%

Pharmacological treatment of obesity

Mancini

Halpern

2006

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.

show abstract

“…Entretanto, a resposta de GH ao GHRH é aumentada com dexfenfluramina em pacientes com obesidade andróide e os níveis de insulina foram reduzidos (embora esta última resposta possa ter sido influenciada pela dieta) (59). Outros autores não observaram aumento da resposta de GH ao GHRH em mulheres obesas submetidas a tratamento com dexfenfluramina (60). O mazindol leva à redução da insulina e do GH durante teste oral de tolerância à glicose e promove elevação de T 4 , embora não altere FSH, LH, testosterona, renina, angiotensina II, taxa metabólica basal, reflexo aquileu e 17-cetosteróides (61).…”

Section: Farmacocinética Clínicaunclassified

Tratamento Farmacológico da Obesidade

Mancini

Halpern

2002

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

A informação apresentada nesta revisão oferece uma visão da terapêutica corrente, bem como de medicamentos que já foram extensamente utilizados e que não mais estão disponíveis ou não são considerados classicamente agentes anti-obesidade. Os autores realizam uma extensa revisão sobre os critérios de avaliação de eficácia de tratamentos anti-obesidade, sobre agentes farmacológicos derivados beta-fenetilamínicos (anfepramona, fenfluramina, dexfenfluramina, fentermina e sibutramina), derivados tricíclicos (mazindol), derivados fenilpropanolamínicos (efedrina, fenilpropanolamina), derivado oxitrifluorfenil da fenilpropanolamina (fluoxetina), derivado naftilamínico (sertralina) e derivado da lipstatina (orlistat). É apresentada uma análise de todos os estudos clínicos de mais de dez semanas de duração com medicamentos usados no tratamento da obesidade.

show abstract

Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women

Abstract: This study confirms that GH secretion in response to stimuli with varying mechanisms of action is blunted in obese subjects. A decrease of central serotonin mediated neurotransmission does not appear to play a role in the pathogenesis of this phenomenon.

Cited by 7 publications

References 28 publications

Treatment of obesity: an update on anti‐obesity medications

Treatment of obesity: an update on anti‐obesity medications

Pharmacological treatment of obesity

Tratamento Farmacológico da Obesidade

Contact Info

Product

Resources

About